A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS

被引：0
作者：
Shah, S. N. [1 ]
Wissinger, E. [2 ]
Ballew, N. [2 ]
Hepp, Z. [3 ]
机构：
[1] Astellas Pharma Inc, Northbrook, IL USA
[2] Xcenda LLC, Palm Harbor, FL USA
[3] Seattle Genet, Bothell, WA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN40
引用
收藏
页码：S443 / S443
页数：1
相关论文
共 50 条
[21]   Efficacy and safety of PD-1/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis [J].
Zhang, Dongli ;
Shen, Chong ;
Zhang, Weichuan ;
Chen, Haibin ;
Zhao, Jianjun .
FRONTIERS IN IMMUNOLOGY, 2025, 16
[22]   FIRST-LINE TREATMENT PATTERNS AMONG PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (LA/MUC): A SYSTEMATIC LITERATURE REVIEW [J].
Kearney, M. ;
Zhang, L. ;
Hubscher, E. ;
Musat, M. ;
Harricharan, S. ;
Wilke, T. .
VALUE IN HEALTH, 2022, 25 (12) :S414-S414
[23]   Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis [J].
Wen, Wen ;
Zhang, Yong ;
Zhang, Hua ;
Chen, Yingshuang .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) :969-978
[24]   Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis [J].
Wen Wen ;
Yong Zhang ;
Hua Zhang ;
Yingshuang Chen .
Journal of Cancer Research and Clinical Oncology, 2023, 149 :969-978
[25]   Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis [J].
Yin, Gaofei ;
Guo, Wei ;
Duan, Hanyuan ;
Huang, Zhigang .
CLINICAL OTOLARYNGOLOGY, 2021, 46 (05) :1013-1020
[26]   Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI). [J].
Shah, Manasee ;
Devine, Jacob ;
Wang, Sam ;
Hepp, Zsolt ;
Shah, Sonali .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[27]   Patient-reported outcome (PRO) assessment and reporting in first-line (1L) locally advanced or metastatic urothelial cancer (la/mUC) clinical trials: Results of a systematic literature review (SLR). [J].
Kearney, Mairead ;
Macmillan, Tom ;
Poritz, Julia ;
Schreiber-Gosche, Sherrie ;
Musat, Mihaela Georgiana .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[28]   Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy [J].
Morgans, Alicia K. ;
Grewal, Simrun ;
Hepp, Zsolt ;
Fuldeore, Rupali ;
Odak, Shardul ;
Macahilig, Cynthia ;
Shillington, Alicia C. ;
Sonpavde, Guru .
CLINICAL GENITOURINARY CANCER, 2022, 20 (06) :543-552
[29]   Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis [J].
Ding, Jianqiao ;
Liu, Zheyu ;
Ning, Jing ;
Sun, Nan .
EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (03) :259-267
[30]   The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis [J].
Wang, Bi-Cheng ;
Cao, Ru-Bo ;
Fu, Chen ;
Chen, Wang-Bing ;
Li, Pin-Dong ;
Lin, Guo-He ;
Qian, Xiao-Jun ;
Li, Yun-Tian ;
Liu, Quentin .
ORAL ONCOLOGY, 2020, 104
12345